Compare MLAB & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLAB | BCYC |
|---|---|---|
| Founded | 1982 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 447.4M | 476.6M |
| IPO Year | N/A | 2019 |
| Metric | MLAB | BCYC |
|---|---|---|
| Price | $89.26 | $6.51 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 11 |
| Target Price | ★ $83.00 | $18.73 |
| AVG Volume (30 Days) | 102.8K | ★ 247.3K |
| Earning Date | 02-03-2026 | 02-24-2026 |
| Dividend Yield | ★ 0.72% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $245,255,000.00 | $28,339,000.00 |
| Revenue This Year | $4.96 | N/A |
| Revenue Next Year | $5.27 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.39 | N/A |
| 52 Week Low | $55.45 | $6.03 |
| 52 Week High | $155.12 | $14.95 |
| Indicator | MLAB | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 65.53 | 43.09 |
| Support Level | $80.00 | $6.37 |
| Resistance Level | $89.95 | $6.88 |
| Average True Range (ATR) | 4.23 | 0.32 |
| MACD | 0.40 | -0.02 |
| Stochastic Oscillator | 88.59 | 23.63 |
Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in four divisions: Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. Clinical Genomics division develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables. The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. The Calibration Solutions division develops, manufactures, sells, and services quality control products.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.